- Home
- KXIN vs INAB Comparison
KXIN vs INAB Comparison
Compare KXIN & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KXIN
- INAB
- Stock Information
- Founded
- KXIN 2015
- INAB 2016
- Country
- KXIN China
- INAB United States
- Employees
- KXIN N/A
- INAB N/A
- Industry
- KXIN Retail-Auto Dealers and Gas Stations
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- KXIN Consumer Discretionary
- INAB Health Care
- Exchange
- KXIN Nasdaq
- INAB Nasdaq
- Market Cap
- KXIN 13.0M
- INAB 14.5M
- IPO Year
- KXIN N/A
- INAB 2021
- Fundamental
- Price
- KXIN $0.90
- INAB $2.08
- Analyst Decision
- KXIN
- INAB Strong Buy
- Analyst Count
- KXIN 0
- INAB 2
- Target Price
- KXIN N/A
- INAB $108.00
- AVG Volume (30 Days)
- KXIN 80.5K
- INAB 285.0K
- Earning Date
- KXIN 01-01-0001
- INAB 08-07-2025
- Dividend Yield
- KXIN N/A
- INAB N/A
- EPS Growth
- KXIN N/A
- INAB N/A
- EPS
- KXIN N/A
- INAB N/A
- Revenue
- KXIN N/A
- INAB N/A
- Revenue This Year
- KXIN N/A
- INAB N/A
- Revenue Next Year
- KXIN N/A
- INAB N/A
- P/E Ratio
- KXIN N/A
- INAB N/A
- Revenue Growth
- KXIN N/A
- INAB N/A
- 52 Week Low
- KXIN $0.64
- INAB $2.06
- 52 Week High
- KXIN $29.54
- INAB $27.30
- Technical
- Relative Strength Index (RSI)
- KXIN 53.15
- INAB 26.25
- Support Level
- KXIN $0.90
- INAB $2.10
- Resistance Level
- KXIN $1.10
- INAB $2.31
- Average True Range (ATR)
- KXIN 0.06
- INAB 0.15
- MACD
- KXIN 0.01
- INAB 0.03
- Stochastic Oscillator
- KXIN 48.98
- INAB 1.16
About KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.